Faron Pharmaceuticals
1.19 EUR -0.67%Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreLatest research
Extensive report
Analyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Citibank Europe PLC | 32.6 % | 32.6 % |
Skandinaviska Enskilda Banken AB | 8.5 % | 8.5 % |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.7 | 5.6 |
growth-% | 66,751.7 % | 110.1 % | ||||||
EBITDA | -16.4 | -20.8 | -27.4 | -28.2 | -29.5 | -31.0 | -29.7 | -26.5 |
EBIT (adj.) | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -29.9 | -26.6 |
EBIT | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -29.9 | -26.6 |
Profit before taxes | -16.9 | -21.2 | -28.7 | -30.9 | -32.5 | -33.8 | -32.8 | -29.8 |
Net income | -16.9 | -21.2 | -28.6 | -30.9 | -32.5 | -33.8 | -32.8 | -29.8 |
EPS (adj.) | -0.36 | -0.40 | -0.48 | -0.45 | -0.31 | -0.32 | -0.31 | -0.28 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -409,275.0 % | -520,050.0 % | -685,675.0 % | -705,550.0 % | -738,215.0 % | -775,945.0 % | -1,112.4 % | -471.3 % |
EBIT-% (adj.) | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -1,118.5 % | -473.8 % |
EBIT-% | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -1,118.5 % | -473.8 % |
ROE | 14,063.1 % | -3,920.3 % | 670.4 % | 232.3 % | 230.8 % | 113.0 % | 51.8 % | 31.5 % |
ROI | -676.3 % | -588.9 % | -707.3 % | 7,250.8 % | 4,536.4 % | -3,566.0 % | -3,964.7 % | -4,039.8 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.91 | 3.24 | 3.41 | 3.77 | 1.19 | 1.19 | 1.19 | 1.19 |
Shares | 46.9 | 53.2 | 59.8 | 68.8 | 104.8 | 104.8 | 104.8 | 104.8 |
Market cap | 136.5 | 172.5 | 203.6 | 259.3 | 124.7 | 124.7 | 124.7 | 124.7 |
Enterprise value | 135.1 | 169.0 | 209.6 | 265.3 | 131.7 | 165.4 | 198.1 | 227.8 |
EV/S | 33,775.4 | 42,241.4 | 52,395.5 | 66,337.2 | 32,928.1 | 41,354.2 | 74.1 | 40.5 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 58.8 | - | - | - | - | - | - |
P/S | 34,117.3 | 43,117.9 | 50,904.8 | 64,831.5 | 31,184.0 | 31,184.0 | 46.6 | 22.2 |
Dividend yield | ||||||||
Equity ratio | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -124.8 % | -454.7 % | -780.9 % | -1,081.7 % |
Gearing ratio | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -53.5 % | -86.8 % | -92.1 % | -94.2 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -12.6 | -15.6 | -28.2 | -13.9 | -15.7 | ||||
EBIT | -12.8 | -15.8 | -28.6 | -14.1 | -15.9 | ||||
Profit before taxes | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 | ||||
Net income | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 |
Login required
This content is only available for logged in users
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
PREMIUM account
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: New shares registered with Finnish Trade Register
Redeye: Faron Pharmaceuticals - Approaching pivotal studies
Faron Pharmaceuticals Oy: Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering
![Faron Pharmaceuticals Company Event](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1e9592d0-56c3-4f7b-9979-3e6c98ad283c.png)
Faron Pharmaceuticals Company Event
Faron Pharmaceuticals Oy: Proposed REX Retail Offer
Faron Pharmaceuticals Oy: Faron commences a share offering
![Faron Pharmaceuticals, BEXMAB Study Update](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/8996d141-ea59-4774-a573-17370363c7df.png)